Hospital of the University of Pennsylvania Department of ...

Department of Pathology and Laboratory Medicine – Reference Ranges

Hospital of the University of Pennsylvania

Department of Pathology and Laboratory Medicine

3400 Spruce Street

Philadelphia, PA 19104

Reference Ranges Oct. 2018 – Oct. 2019

Title: Assay Reference Ranges and/or Interpretive Comments

analyte Alpha fetoprotein, AFP

Beta 2 Microglobulin, BMGCA125

CA15-3CA19-9

CEAC-peptide

Females Males(Age yrs.) (Age yrs.)

18-21 51-321 18-21 24-53721-30 18-391 21-30 85-69031-40 23-266 31-40 106-46441-50 19-231 41-50 70-49551-60 8-188 51-60 38-31361-70 12-133 61-70 24-244≥ 71 7-177 ≥ 71 5-253

Males <15 - 31.5 pg/mLFemales

Early Follicular 22.4 – 115 pg/mLMid-Follicular Phase 25-115 pg/mL

Ovulatory Peak 32.1 – 517 pg/mLMid Luteal Phase 36.5 – 246 pg/mLPost-Menopausal <25.1 pg/mL

Erythropoetin, EPOMales 1.27 – 19.26 mIU/mLFemales

Mid-Follicular Phase 3.85 – 8.78 mIU/mLMid-Cycle Peak 4.54 – 22.51 mIU/mL

Mid-Luteal Phase 1.79 – 5.12 mIU/mLPost-Menopausal 16.74 – 113.59 mIU/mL

Growth Hormone

Hemoglobin A1c

HCG, Oncology Homocysteine

Total IgE< 0.1 kU/L Not Detectable

0.1 – 0.34 kU/LVery Low (Clinical relevance indeterminate)

0.35 – 0.70 kU/L Low0.71 – 3.50 kU/L Moderate

3.51 – 17.50 kU/L High>17.5 kU/L Very High

Insulin

The level of growth hormone in serum is subject to wide and sometimes rapid fluctuations during the day, and may be altered

greatly by normal physiological events. Therefore, results obtained from a single random specimen are difficult to interpret and challenge

tests may be required to establish a diagnosis.

Male: <5 mIU/mL Female, Non-Pregnant: <5 mIU/mL

1.1-2.4 mg/L0 - 35 U/mL0 - 25 U/mL0 - 35 U/mL

0 - 4.7 ng/mL

Interp comments

Effective date: 10/16/2018Prepared By: Nichole Rulander

µg/dL

Estradiol, E2

Follicle Stimulating Hormone, FSH

4.0 - 5.6 %

4-12 µmol/L2 – 214 kU/L

2.6- 24.9 mIU/L

reference ranges

Allergen Specific IgE <=0.34 kU/L

Patients with an AMH concentration < 0.7 ng/mL frequently have < 3 antral follicles. Women with serum AMH > 2.0 ng/mL may benefit from

decreased ovarian stimulation dosing to avoid hyperstimulation. Women with polycystic ovarian syndrome have approximately 3-fold

elevated results (median: 7 ng/mL, 5th percentile: 3 ng/mL)

3 - 19 mIU/mL

1.1 - 4.4 ng/mL

DHEA-S

µg/dL

Hospital of the University of PennsylvaniaDepartment of Pathology and Laboratory

Section: ENDOCRINOLOGY

Anti- Mullerian Hormone, AMH

Females, Age yrs.

25 - 2930 - 3435 - 3940 - 44

0.89 - 9.85 ng/mL0.58 - 8.13 ng/mL0.15 - 7.49 ng/mL0.03 - 5.47 ng/mL

20 - 24 1.22 - 11.7 ng/mL

0 -5 IU/mL

Males 1.24 – 8.62 mIU/mLFemales

Mid-Follicular Phase 2.12-10.89 mIU/mLMid-Cycle Peak 19.18-103.03 mIU/mL

Mid-Luteal Phase 1.20-12.86 mIU/mLPost Menopausal 10.87-58.64 mIU/mL

Progesterone

Males 2.64 - 13.13 ng/mLFemales

pre-menopausal (<50 years of age)

3.34-26.72 ng/mL

post-menopausal (≥50 years of age)

2.74-19.64 ng/mL

Parathyroid Hormone, PTH

TestosteroneThyroglobulin

Thyroglobulin-AbTPO-Ab

Tryptase HIV Ag/Ab

HCVHepatitis B Surface Ag

Hepatitis B Surface antibody Hepatitis B CORE antibody

Hepatitis B CORE-IgMHepA-IgG

HepA-IgM

Adult Males 20 - 49 years: 249 - 836 ng/dL

Adult Males >50 years: 193 - 740 ng/dL

1.6-6.9 pmol/L

1.59 - 50.0 ng/mL≤3.9 U/mL

Adult Female (>17 yrs): Follicular Phase: <0.8 - 1.1 ng/mL

Midcycle: <0.8-1.7 ng/mL Luteal phase: 0.9 - 21.0 ng/mL

Oral contraceptives: <0.8-1.0 ng/mL Postmenopause: <0.8-1.0 ng/mL

Ist trimester pregnancy: 9.3 - 33.2 ng/mL 2nd trimester pregnancy: 29.5 - 50.0 ng/mL 3rd trimester pregnancy: 83.1 - 160.0 ng/mL

Adult Male (>17 yrs): <0.8 - 0.9 ng/mL

Prolactin

Luteinizing Hormone, LH

≤8.9 U/mL

Qualitative, no reference ranges

≤8.9 U/mL

THERAPEUTIC RANGES page 1 of 2

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA

DIVISION OF LABORATORY MEDICINE

TOXICOLOGY LABORATORY

TEST THERAPEUTIC RANGE CRITICAL VALUE

Amikacin Trough Less than 8 mg/L Trough: >10 mg/L

Peak (1) Patients on once-daily dosing: 40 - 60 mg/L Peak: >30 mg/L

(2) Patients on traditional dosing: 20 - 30 mg/L

Cyclosporine Kidney Transplants >500 mcg/L

100-250 mcg/L, first three months post transplant.

80-125 mcg/L, after three months post transplant.

Heart Transplants

200-300 mcg/L, first twelve months post transplant.

100-150 mcg/L, after first year post transplant.

Liver Transplants

200-300 mcg/L.

Lung Transplants

250-350 mcg/L, first twelve months post transplant.

200-300 mcg/L, after first year post transplant.

Bone Marrow Transplants

200-250 mcg/L.

Ethanol None detected. >80 mg/dL

Everolimus 3.0 - 8.0 ng/mL

Isopropanol None detected. >50 mg/dL

Lamotrigine 2.5 - 15 mg/L

Levetiracetam (Keppra) 12 - 46 mg/L

Lidocaine 1.5-5.0 mg/L >5 mg/L

Methanol None detected. >10 mg/dL

Methotrexate The therapeutic range for methotrexate is protocol dependent. For specimens

obtained 48 hours after initiation of a methotrexate infusion, the range is

0.05 to 0.10 umole/L.

MPA (mycophenolic acid) 1.0 - 3.5 mg/L (following an overnight fast)

Phenytoin, Free 1.0 - 2.0 mg/L

Rapamycin 4.0--12.0 ng/mL

THERAPEUTIC RANGES page 2 of 2

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA

DEPARTMENT OF LABORATORY MEDICINE

TOXICOLOGY LABORATORY

TEST THERAPEUTIC RANGE CRITICAL VALUE

Tacrolimus Renal transplant patients > 20 ug/L

(FK506) 0-3 months, 8-10 ug/L

4-6 months, 6-8 ug/L


> 12 months, 4-6 ug/L

Heart transplant patients

0-3 months, 10-12 ug/L > 20 ug/L

3-6 months, 10 ug/L


> 12 months, 5-8 ug/L

Liver transplant patients

1st week, 10-20 ug/L

1-4 weeks, 5-15 ug/L

> 4 weeks, 5-10 ug/L

Lung transplant patients


>12 months, 6-8 ug/L

Bone marrow transplant patients

5-15 ug/L

Topiramate 5 - 20 mg/L

Vitamin D, 25-hydroxy, Total 25 - 80 ng/mL

Zonisamide 10 - 40 mg/L

_______________________

Dr. Leslie Shaw

9/7/2018

Hemoglobin ID Normal Reference Ranges

Hgb A 95 – 98% Hgb A2 1.5 - 3.5% Hgb F 0 – 1% MCV 80 – 100 fl Hgb (Females) 12.0 – 16.0 g/dL Hgb (Males) 13.5 – 17.0 g/dL

Bone Marrow Diff Blasts BM 0-4% Promyelo BM 0-8% Meta/Myelo BM 18-41% Segs/Bands BM 7-32% Monocyte BM 0-2% Eos BM 0-4% Basophil BM 0-1% Lymph BM 5-20% Plasma Cell BM 0-3% NRBC BM 8-35%

Penn Medicine

Hospital of the University of Pennsylvania

Department of Pathology and Laboratory Medicine

Division of Laboratory Medicine

Section: Point of Care Testing

Page 1 of 6

Version: 1.0

Title: Point of Care Reference Ranges Effective: 5/26/20166/7/2016

Modified: 9/21/2017

Print Status: Uncontrolled When Printed

AccuChek Inform II Units Whole blood glucose 70-99 mg/dL Abbott i-STAT Troponin I 0.00-0.08 ng/mL DCA Vantage Hemoglobin A1C 4.0%-6.0%

Hemochron Signature Elite

Prothrombin Time 10.7-13.8 Seconds

INR 0.9-1.1

Prothrombin Time/INR: Result of the Prothrombin time is reported in seconds and is converted to the international normalized ratio (INR). The INR is a calculation based on the result of the prothrombin time and serves to standardize results from different laboratories and the variable response to different thromboplastin reagents. Recommended therapeutic warfarin range is patient specific and is determined by the physician/provider

Activated Clotting Time Ranges are established by the testing unit and the procedure that is being performed.

Radiometer ABL 90 Flex

Blood Gas

Test Age Arterial Units

pH 0 to 2D 7.29 to 7.45

Reference Sheets page 2 of 6

POCT Reference Ranges 2017 6/7/2016


2D to 1M 7.31 to 7.45

1M to 2Y 7.34 to 7.44

2Y to 19Y 7.37 to 7.44

>19 Y 7.35 to 7.45

pCO2 0 to 1W 27 to 40 mmHg

1W to 1M 30 to 42 mmHg

1M to 2Y 30 to 44 mmHg

2Y to 19Y 31 to 47 mmHg


>21Y 34 to 45 mmHg

pO2 0 to 1W 54 to 95 mmHg

1W to 1M 65 to 98 mmHg

1M to 2Y 80 to 105 mmHg



>21Y 75 to 100 mmHg

HCO3 0 to 1W 16 to 22 mmol/L

1W to 1M 18 to 24 mmol/L

1M to 2Y 18 to 25 mmol/L

2Y to 19Y 20 to 26 mmol/L




19Y to 21Y 22 to 27 mmol/L

>21Y 22 to 26 mmol/L

Sodium-Na+ 0 - 1M 132 to 145 mmol/L

1M - 1Y 134 to 144 mmol/L

>1Y 133 to 143 mmol/L

Potassium-K+ 0 - 1Y 4.0 to 6.2 mmol/L

>1Y 3.5 to 5.3 mmol/L

Chloride O minute to 1 month 98-106 mmol/L

> 1 month 96 -110 mmol/L

Hematocrit 0-1D 42-60 %

1D-1M 45-65 %

1M-3M 31-55 %

3M-6M 29-41 %

6M-150y Male 42 to 51 %

6M-150y Female 33 to 45 %

Hemoglobin 0-1D 13.5 to 19.5 g/dL

1D-1M 14.5 to 22.0 g/dL

1M-3M 10.0 to 18.0 g/dL

3M-6M 9.5 to 13.5 g/dL

6M-150y Male 13.5 to 17.5 g/dL




6M-150y Female 12.0 to 16.0 g/dL

Glucose 0 – 1Y 70-99 mg/dL

>1Y 70-99 mg/dL

Ionized Calcium

1.00 to 1.25 mmol/L

Lactate 0.5-1.6 mmol/L

sO2 94.0-99.0 %

O2Hgb > 1month 94.0-99.0 %

O2 content 16 - 23 mL/dL

COHgb 0.5-1.5 %

(interpretive comment: "Chronic heavy smokers may have levels up to 10%.")

MetHgb 0-1.4 %

Base Excess (-3) - (+3)

Test Age Venous Units

pH 7.31 to 7.41

pO2 30 to 45 mmHg

pCO2 40 to 50 mmHg

Lactate 0.5-2.2 mmol/L

HCO3 0 – 2Y 22 to 29 mmol/L




>2Y 22 to 29 mmol/L

Sodium-Na+ 0 - 1M 132 to 145 mmol/L

1M - 1Y 134 to 144 mmol/L

>1Y 133 to 143 mmol/L

Potassium-K+ 0 to 1Y 4.0 to 6.2 mmol/L

>1Y 3.5 to 5.3 mmol/L

Chloride O minute to 1 month 98-106 mmol/L

> 1 month 96 -110 mmol/L

Ionized Calcium

1.00 to 1.25 mmol/L

sO2 70-80 %

O2Hgb 40-85 %

COHgb 0.5-1.5 %

(interpretive comment: "Chronic heavy smokers may have levels up to 10%.")

MetHgb 0-1.4% %

Glucose 0 – 1Y 70-99 mg/dL

>1Y 70-99 mg/dL

Base Excess -3 to +3 mg/dL

Hematocrit 0-1D 42-60 %

1D-1M 45-65 %




1M-3M 31-55 %

3M-6M 29-41 %

6M-150y Male 42 to 51 %

6M-150y Female 33 to 45 %

Hemoglobin 0-1D 13.5 to 19.5 g/dL

1D-1M 14.5 to 22.0 g/dL

1M-3M 10.0 to 18.0 g/dL

3M-6M 9.5 to 13.5 g/dL

6M-150y Male 13.5 to 17.5 g/dL

6M-150y Female 12.0 to 16.0 g/dL

Copy- Not Transferrable

Hospital of the University of Pennsylvania Department of ...

Documents

Transcript of Hospital of the University of Pennsylvania Department of ...